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First cohorts of human papillomavirus (HPV)-vaccinated women are reaching the screening ages 
and there is an increasing need to redesign cervical cancer screening programs. Less frequent 
screening in HPV-vaccinated birth-cohorts could produce considerable savings without increasing 
cervical cancer incidence. We report here baseline findings and interim results of safety of 
infrequent screening among HPV16/18-vaccinated females. Cervical high-grade lesions showed 




Less frequent cervical cancer screening in human papillomavirus (HPV) vaccinated birth cohorts 
could produce considerable savings without increasing cervical cancer incidence and loss of life-
years. We report here the baseline findings and interim results of safety and accuracy of infrequent 
screening among HPV16/18 vaccinated females. The entire 1992-94 birth-cohorts (30139 females) 
were invited to a community-randomized HPV16/18-vaccination trial. A total of 9,482 female trial 
participants received HPV16/18-vaccinationin 2007-09 at age of 13-15. At age 22, 4273 (45%) of 
these females consented to attend a randomized trial on frequent (ages 22/25/28)(Arm 1: 
2073females) vs. infrequent screening (age 28)(Arm 2: 2200females) in 2014-2017. Females 
(1329), who had got HPV16/18 vaccination at age 18 comprised the safety Arm 3. Baseline 
prevalence and incidence of HPV16/18 and other high-risk HPV types were: 0.5% (53/1000 
follow-up years, 104) and 25% (2530/104) in the frequently screened Arm 1; 0.2% (23/104) and 
24% (2,413/104) in the infrequently screened Arm 2; and 3.1% (304/104) and 23% (2284/104) in 
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the safety Arm 3.Corresponding prevalence of HSIL/ASC-H and of any abnormal cytological 
findings were:0.3% and 4.2% (Arm 1), 0.4% and 5.3% (Arm 2), and 0.3% and 4.7% (Arm 
3).Equally rare HSIL/CIN3 findings in the infrequently screened safety Arm A3 (0.4%) and in the 
frequently screened Arm 1 (0.4%)indicate no safety concerns on infrequent screening despite the 








Prophylactic human papillomavirus (HPV) vaccines have proven to be safe and efficacious 
against cervical cancer as other anogenital and oral infections with low risk (lr) - and high-risk 
(hr) -HPV types, and associated neoplasia [1-4]. HPV vaccines are being implemented in 
vaccination programmes in both developing and developed countries. They have reported 
significant reductions in the prevalence of hrHPV infections and related cervical lesions, 
provided that generally high coverage has been achieved [4-6]. Rapid changes in the screening 
performance, especially deterioration of the positive predictive values of all screening tests, are 
imminent. [7] At the same time the overuse of cervical screening with obvious harms is a 
concern. [8] Now, that the first cohorts of HPV vaccinated women are reaching the screening 
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ages, there is an increasing need to redesign cervical cancer screening programs, to reduce the 
number of screening visits, and to synchronize tools for future cervical cancer prevention. 
 
The superior sensitivity of molecular HPV-DNA testing as compared to Pap-testing in screening 
for cervical cancer precursors has been verified in multiple randomized trials. [9-12] Many 
countries have changed or are changing their screening programs towards HPV-Primary 
Screening. [13] Consequently cervical screening practices are rapidly changing for both 
unvaccinated and vaccinated birth cohorts. Mathematical models suggest that with high HPV 
vaccination coverage (80% or above) the screening interval can be increased up to 20 years with 
no change in cervical cancer incidence. [14] Integration of the vaccination and screening 
programs has, however, received relatively little attention. [15] 
 
Nordic screening programs, which apply 3 to 5-year intervals resulting in10 or more life-time 
screening visits with reasonably high overall coverage, have not been able tackle HPV-disease 
burden associated with epidemic spread of HPV16. [16,17] Furthermore, despite e.g. most young 
Finnish women attend opportunistic cervical screening every second year since the start of oral 
contraception, the incidence of cervical cancer in Finland between 25-39 years of age is now 
higher than at the start of cervical screening 50 years ago. [17-19] At the same time, 
opportunistic screening tests which comprise over 60% of all tests, identify mostly lesions that 
would have regressed spontaneously. [18] Furthermore, the costly over-diagnostics, follow-up 
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and treatment of the mostly (90%) spontaneously regressing HPV DNA positive cytological 
findings also reduces the quality-of-life. [20] 
 
Prophylactic HPV vaccination program provision of up to 93% vaccine efficacy against CIN3+ 
is crucial in reducing the number of screening visits in vaccinated women. [21] Increase of both 
the number of quality-assured life-years gained, and improved quality-of-life by subsequent 
vaccination and reduced number of screening and follow-up visits of the vaccinated women are 
now within reach. In the following, we describe baseline findings of a randomized trial launched 
to assess how the number of screening visits can be reduced from three visits to one visit in 
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HPV16/18 vaccination was performed at the health care facilities in all the 250 municipal junior 
high schools of the 33 trial communities in 2007-2009 (Figure 1). [22] All the vaccinated 
participants in the 1992-94 birth cohorts received Cervarix® (AS04-HPV-16/18) –vaccine at age 
13-15 (Arms A1 and A2) or at age 18 (Arm A3). Altogether 9482 HPV16/18 vaccinated and 
3872HPV16/18 cross-vaccinated female participants, who had received hepatitis B-virus vaccine 
in the community-randomized trial, were eligible at age 22 to attend the trial.Virtually all (99.4% 
and 86.3% of those vaccinated at the ages of 13-15 years old and 18 years old, respectively) of 
them received three vaccine doses. 
 
All 1992-94 born females, resident in the trial communities (Supplementary Table 1), were eligible 
to attend and were invited to the randomized screening trial at ages 22, 25 and 28 years, provided 
that they had received HPV16/18 vaccination. After obtaining informed consent pelvic 
examination, cytological Pap-smear and a cervicovaginal self-sample for HPV and Chlamydia 
trachomatis DNA-testing were obtained at the first and second screening visits at ages 22 and 25. 
 
Study design, formation of randomized cohorts and study events in the screening of HPV-vaccines 
trial are outlined in Figure 1. All participants in Arms A1 and A2 will attend three visits during 
which cervical samples are taken. In the frequently screened arm A1, the participants will receive 
all information on cytological findings at ages 22, 25 and 28. In the infrequently screened arm A2, 
the participants will receive only information indicative of colposcopy (ASC-H, HSIL, AGC) at 
ages 22, 25 and 28. In the safety arm A3 the participants, who had received HPV16/18 vaccine as 
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cross-vaccination at age 18, attend two visit only. At age 22 they receive only information on 
cytological findings indicative of colposcopy. At the trial end (Arms 1 and 2, age 28, Arm 3, age 
25), all cytological findings and HPV DNA findings will be conveyed to all the trial participants. 
 
Laboratory analyses  
All samples are analyzed for genotypes specific HPV-DNA using matrix-assisted laser desorption 
time-of-flight (MALDI-TOF) mass spectrometry for the detection of HPV6/11/16/18/ 
31/33/35/39/45/51/52//56/58/59/66/ and 68. [23, 24] MGP consensus primers are used followed 
by a mass extension reaction with type-specific primers that each have a unique molecular weight 
for a specific type. Following completion of the mass extension reaction, unextended primers 
demonstrate the absence and extended primers show the presence of each specific genotype. 
Confirmative testing, using Luminex was performed on all positives for HPV11/68 due to a cross-
reaction between the primers for HPV11/89 and HPV68/70.Chlamydia trachomatis DNA analysis 
is performed with the Abbott Real Time CT/NG assay.  
 
Statistical analysis and Study power 
The interim analyses were performed for the first screening visit observations in the 1992, 1993, 
1994 -born participants under 11-month time-windows during 2014, 2015-2016 and 2016. Safety 
was analyzed in the 1992 and 1993 born participants during 2014-18. Descriptive statistics and 
prevalence/incidence (/10,000 follow-up years between 18 and 22 years of age) estimates of the 
baseline HPV DNA and/or cytological findings were estimated STATA (Stata Corp, LLC, US). 
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Analyses or non-inferiority end-point findings between the different trial arms, and estimates for 
screening sensitivity, specificity and predictive values will be estimated by STATA. 
The lowest detectable sensitivity (71.6%) to exclude non-inferiority in the identification of CIN2+ 
in 7000 frequently vs. infrequently screened 30-year-old women assuming 95% specificity of 




Our trial (NCT02149030) has been approved by the Pirkanmaa Hospital District Ethical Review 
Board in 2013. 
 
Data availability 



















Our two randomized trial arms A1 (frequently screened) and A2 (infrequently screened) comprise 
consented 22-year-old female attendees (2073 and 2200, respectively), who got the HPV16/18 
vaccine as early adolescents (ages 13 to 15) in 2007-2009. Females (1329) cross-vaccinated with 
the HPV16/18 vaccine at age 18 in 2010-2013 consented to participate in a separate safety arm A3 
for infrequent screening. Almost all (97%) of the consented females participated the 1st screening 
visit with cervical sampling (Figure 2).   
 
Stepwise trial enrolment at age 22 was identical in each birth cohort (Figure 3). There was no 
difference in the attendance whether HPV16/18 vaccination had taken place already in early 
adolescence at ages 13 to 15 or at the age of 18 (cross-vaccination) (Figure 3). As for the 1992and 
1993 birth cohorts which have already attended the 2nd screening round visits, 89% and 86% of 
the 1st screening round participants have participated (Figure 4). 
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There were no material differences in the demographic or sexual risk-behaviour characteristics of 
the screening trial participants (Table 1). The number of individuals with five or more sexual 
partners by the age of 22 was somewhat higher in those, who had received HPV16/18 vaccination 
as early adolescents (42.5% both Arms 1 and 2), as compared to those who received HPV16/18 
vaccination at the age of 18 (38.6%, Arm 3). Corresponding C. trachomatis prevalence at age 
22were 2.4% and 2.3% (Arms 1 and 2), and 1.5% (Arm 3).  
 
HPV16/18 DNA prevalence and incidence at the first screening visit (at age 22) were notably rare 
in both the frequently and infrequently screened Arms A1 and A2 (0.5% and 0.2%, and 53/104 and 
23/104) as compared to the safety Arm A3 (3.1% and 304/104) which had received HPV16/18 
vaccination at age 18 (Table 2). Also, the prevalence (and incidence) of vaccine-covered HPV 
types 31/33/45 was about two times lower among Arm 1 and Arm 2 participants, who had been 
vaccinated between 13-15 years of age as compared to Arm 3 participants (A1 2.8%, A2 2.3%, A3 
5.3%, Table 2).Corresponding prevalence (and incidence) of overall hrHPV types were materially 
equal between the three arms (A1 27%, A2 26%, A3 27%). 
 
Abnormal cytological findings at the 1st screening visit (at age 22) showed no major differences 
between the different screening arms. Prevalence of ASCUS findings varied from 3.1% to 4.5%, 
between the three arms (Table 3). The prevalence of LSIL findings was highest in Arm 1 (Table 
3), but the overall prevalence of these mild cytological findings varied within a narrow range of 
5.1% to 5.9%. The prevalence of ASC-H/HSIL findings were comparable in the frequently 
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screened Arm A1 (0.3%) and the infrequently screened Arms A2 (0.2%), and the safety Arm A3 
(0.3%). 
 
Interim safety analysis of infrequent screening among the cross-vaccinated females was performed 
at the end of 2018 when virtually all participants from the 1992 and 1993 birth cohorts had attended 
the 2nd screening visit (Figure 4). There were three (0.4%) HSIL/CIN3 cases found in 824 
infrequently screened, cross-vaccinated Arm A3 participants as compared to six (0.4%) 
HSIL/CIN3 cases in 1280 frequently screened Arm A1 participants, who had received HPV16/18 
vaccination early adolescents (Table 4). One of the Arm A3 participants with a HSIL/CIN3 





We report on successful enrolment of three female birth cohorts (1992-94), vaccinated in 2007-
2009 as early adolescents, into a randomized trial to compare frequent vs. infrequent cervical 
screening of HPV vaccinated females at ages 22, 25 and 28. Concomitant enrolment of a sizeable 
cohort of 22-year-old females cross-vaccinated with the HPV16/18 vaccine at age 18 was done.  
The sizeable HPV-vaccinated birth cohorts, now at the screening age from the community-
randomized trial that was launched in Finland in 2007 to identify the HPV vaccination strategy 
with the highest impact. [22]. Homogeneous cytological findings in the different trial arms at 
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baseline assure that enrolment and randomization of the HPV vaccinated females has been 
successful. On the other hand, the impact of getting vaccinated between ages 13 to 15 is seen in 
the very low occurrence of cervical HPV vaccine types, HPV16/18, infections at the first screening 
round (age 22) in the trial Arms A1 and A2 as compared to the similarly-aged safety Arm A3 
which comprises females later cross-vaccinated at age 18. The HPV16/18 occurrence and 
HPV31/33/45 occurrence (prevalence and incidence) were respectively up to 10-fold and 2-fold 
higher in the latter, which fits with relatively early exposure to major hrHPVs of adolescent Finnish 
females and also with the relatively broad cross-protectivity of the HPV16/18 vaccine. [21,22]   
 
Overall, safety in our trial is being guaranteed by sampling all participants on every visit with 
referral of the study participants to diagnosis and treatment pertinent to the cytological results 
according to mandatory local standard of care (HSIL and ASC-H findings), and by the safety 
interim analysis. The safety of infrequent screening could be further confirmed by identical 
occurrence of HSIL/CIN3 lesions in the infrequently and frequently screened females, even if the 
former had received HPV16/18 vaccination at age 18.  The similar low occurrence of HSIL/CIN3 
findings in both arms A3 and A1 indicates that continuing infrequent screening in Arm A2 
participants, who were vaccinated as early adolescents, up to 28 years of age appears safe. The 
study setting will enable assessment of the accuracy of frequent cervical screening (at ages 22, 25 
and 28) vs. infrequent screening (at the age of 28). In addition to safety, randomized trial evidence 
on comparable accuracy of the two screening modes should help to minimize number of screening 
visits in vaccinated young adult women. However, screening results between ages 22 to 25/28 may 
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not be directly related to cervical cancer risk [25] and surveillance of the screening cohorts will be 
warranted also after closing the trial in 2026 – 20 years after it was started.   
 
To the best of our knowledge this is the first randomized trial on the performance of frequent vs. 
infrequent screening of women who have received HPV vaccination as early adolescents. Over 
time infrequent organized screening of HPV vaccinated women would mean considerable (up to 
10-fold) savings compared to the present situation or running two preventive measures (HPV 
vaccination and screening) concomitantly without synchronization. Completing trial enrolment 
with altogether 6995 participants from 1992-1995 birth cohorts we are amply powered to deliver 
randomized-trial evidence on the performance and impact of infrequent screening in HPV 
vaccinated women by the end of 2023. 
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Table 1. Characteristics of HPV16/18 vaccinated womena participating cervical screening and/or 
answering a questionnaire at baseline visit by trial arm: A1 = frequent screening at 22/25/28, A2 = 
infrequent screening at [22/25] /28, and A3 = safety arm, womenb screened at age [22]/ 25.  
 
   A1 (N=2073)         A2 (N=2200)         A3 (N=1329) 
Variable  n/meanc (%/SDc)       n/meanc(%/SD)      n/meanc (%/SD) 
 
Chlamydia   pos.   49 (2.4)    51 (2.3)    20 (1.5) 
trachomatis  neg.             1961 (94.6)                2083 (94.7)                1269 (95.5) 
                     missing   63 (3.0)    66 (3.0)    40 (3.0) 
                     total             2073 (100)                     2200 (100)                      1329 (100) 
          
Age at sexual debut         16.4 (1.9)  16.5 (1.8)     16.6 (1.8) 
 
No. of   0   76 (4.7)                75 (4.4)                 40 (3.8) 
lifetime  1    269 (16.6)           263 (15.4)             201(19.1) 
partners 2    191 (11.8)           203 (11.9)             133 (12.6) 
   3           194 (12.0)            205 (12.0)             124 (11.8) 
  4    185 (11.4)           220 (12.9)             128 (2.2) 
                        >5    689 (42.5)           726 (42.5)             406 (38.6) 
              missing    17 (1.1)                18 (1.1)                  20 (1.9) 
                   total             1620 (100)               1710 (100)               1052 (100) 
 
Smoking      never     932 (57.5)        1015 (59.4)             686 (65.2) 
                    quit   208 (12.8)             192 (11.2)             113 (10.7) 
                current   462 (28.5)          484 (28.3)             244 (23.2) 
     other than cig.        13 (0.8)                     9 (0.5)                       4 (0.4) 
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               missing         6 (0.4)                   10 (0.6)                         5 (0.5) 
                   total            1620 (100)                        1710 (100)                     1052 (100) 
________________________________________________________________________________ 
aHPV16/18 vaccinated as early adolescents between 12 to 15 years of age 
bHPV16/18 cross-vaccinated at 18 years of age  
cmean age (standard deviation) at sexual debut by the baseline  


















Table 2. Baseline HPV DNA findings (prevalence, n1 / incidence (/104), n2) in 22 year-old HPV16/18  
               vaccinated womena  participating cervical screening by trial arm: A1= frequent screening at ages  
 22/25/28, A2=infrequent infrequent screening at age [22/25] /28, A3=safety arm vaccinated 
womenb, screening at age [22] /25.  
 
  A1 (N=1332)         A2 (N=1314)         A3 (N=889) 
HPV type  n1 (%)     /    n2  n1 (%)     /    n2    n1 (%)     /     n2 
_______________________________________________________________________________ 
 
HPV6/11  80 (6.0)     601               61 (4.6)      464  25 (2.8)      281 
 
HPV16     4 (0.3)       30                3 (0.2)        23  22 (2.5)      248 
 
HPV18     3 (0.2)       23                0 (0.0)          0    5 (0.6)        56 
 
HPV31     8 (0.6)       60                9 (0.7)        69  21 (2.4)      236 
 
HPV33   20 (1.5)     150                15 (1.1)      114 19 (2.1)       214 
 
HPV45     9 (0.7)       68                 6 (0.5)        46    7 (0.8)        79 




Other hrHPV 337 (25)    2530                317 (24)     2413          203 (23)      2283 
 
Total hrHPV 365 (27)    2740                339 (26)     2580          242 (27)      2722 
 
Total HPV 406 (31)    3048               365 (28)     2778           254 (29)      2857 
 
 
Missing from  106   139   50 
HPV DNA analysis 
___________________________________________________________________________ 
aHPV16/18 vaccinated as early adolescents between 12 to 15 years of age 
bHPV16/18 cross-vaccinated at 18 years of age 


















Table 3. Baseline cytological findings in 22 year-old vaccinated womena participating cervical screening 
trial arm: A1 =  frequent screening at ages 22/25/28, A2 =  infrequent screening at age [22/25] 
/28, A3 = safety arm vaccinated womenb, screening at age [22]/ 25.  
 
  A1 (N=1438)         A2 (N=1453)         A3 (N=939) 
Finding  n (%)        n (%)       n (%) 
____________________________________________________________________________________ 
 
ASCUS    45 (3.1)                 66 (4.5)                  40 (4.3) 
 
LSIL        23 (1.6)                 13 (0.9)                 8  (0.9) 
 
ASC-H         1 (0.1)      5 (0.3)      2 (0.2)  




AGC/HSIL      5 (0.3)                             3 (0.2)                     3 (0.3) 
 
Total abnormal      74 (5.1)             87 (5.9)               53 (5.6) 
____________________________________________________________________________________ 
aHPV16/18 vaccinated as early adolescents between 12 to 15 years of age 
bHPV16/18 cross-vaccinated at 18 years of age 































Table 4. Interim findings in HPV16/18 vaccinated womena,b  of high-grade squamous intraepithelial 
neoplasia (HSIL/CIN3) diagnosed during a maximum 10 years of post-vaccination follow-up when 
participating  frequent (Arm 1c, n=1280) or infrequent (Arm 3d, n=824) cervical screening at ages 22 and/or 
25 years.  
 
 Birth Vaccination  Cervical HPV DNA findings at           Diagnosis/ 
This article is protected by copyright. All rights reserved.
 
 
Arm year      year Vaccination 1st Screening    2nd Screening              year 
_____________________________________________________________________________________ 
 
A1 1992 2008 not available HPV51/56/66 pending              HSIL/2018 
A1 1993 2008 not available HPV58/68 not available              CIN3/2015 
A1 1993 2008 not available HPV51  not available              CIN3/2016 
A1 1994 2009 not available HPV52/56 not available              HSIL/2018 
A1 1994 2009 not available HPV33  not available              HSIL/2016 
A1 1994 2009 not available HPV35  not available              HSIL/2016 
 
A3 1993 2012 negative HPV31/56/66 pending              CIN3/2017 
A3 1993 2012 negative negative pending             CIN3/2017 
A3 1993 2012 HPV33  HPV33  not available              CIN3/2014 
____________________________________________________________________________________ 
CIN3 = cervical intraepithelial neoplasia grade 3 
aHPV16/18 vaccinated as early adolescents between 12 to 15 years of age 
bHPV16/18 cross-vaccinated at 18 years of age 






































Figure 2. Flow chart of a randomized trial on the accuracy and safety of infrequent vs. frequent 
screening in women who got HPV16/18 vaccination as early adolescents in 2007-2009. 
 
 
Figure 3. Participation to the first round of cervical cancer screening at the age of 22 years by 
birth cohort (1992, 1993, and 1994 -born).  
 
Figure 4. Participation to the second round of cervical screening at the age of 25 years by birth  
                cohort (1992 and 1993 -born).  
 
  












































This article is protected by copyright. All rights reserved.
